Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 25, 2024

Type 2 Inflammation Biomarkers

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Episodes in this series

This series features 1 KOL.

EP. 1 Navigating the Challenges of Respiratory Diseases

1 KOL is featured in this series.

EP. 2 The Impact of Atopic Dermatitis and Prurigo Nodularis

This series features 1 KOL.

EP. 3 Linking Type 2 Inflammation to Asthma and COPD

This series features 1 KOL.

EP. 4 Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

1 KOL is featured in this series.

EP. 5 Type 2 Inflammation: The Link Between AD and PN

1 KOL is featured in this series.

EP. 6 Personalizing Treatment Selection

1 KOL is featured in this series.

EP. 7 Navigating Treatment Challenges in Chronic Skin Conditions

1 KOL is featured in this series.

EP. 8 Role of Biologics in Dermatological Care

This series features 1 KOL.

EP. 9 Biomarkers as Tools in Management of Type 2 Inflammation

This series features 1 KOL.

EP. 10 Strategies to Manage Type 2 Inflammation in Respiratory Diseases

1 KOL is featured in this series.

EP. 11 Addressing Unmet Needs and Emerging Agents

This series features 1 KOL.

EP. 12 Future Directions for Type 2 Inflammation Management

1 KOL is featured in this series.

EP. 13 Type 2 Inflammatory Diseases and Impact on Quality of Life

1 KOL is featured in this series.

EP. 14 Type 2 Inflammation Biomarkers

1 KOL is featured in this series.

EP. 15 How Type 2 Inflammation Influences Treatment Choices

1 KOL is featured in this series.

EP. 16 Complications of Uncontrolled Disease and Management of Comorbidities

1 KOL is featured in this series.

EP. 17 Patient Education and Emerging Therapies

1 KOL is featured in this series.

EP. 18 Unmet Needs and Future Research

What tests or biomarkers are used to determine if a patient’s disease may be caused by type 2 inflammation? How does this information aid your medication selection process?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Mohit Narang, MD.jpeg

Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD

BySabrina McCrear,Mohit Narang, MD

June 29th 2026

Patient coughing and doctor. | Image credit: @Prostock-studio_Adobestock.com

COVID-19 May Follow A Different Seasonal Pattern Than Influenza, RSV

BySabrina McCrear

June 29th 2026

Woman sleeping next to alarm clock - stokkete - stock.adobe.com

Longer Sleep Linked to Lower Glycemic Variability, Reduced Deviation Risk in Adolescents

ByGiuliana Grossi

June 29th 2026

Diagnosing and Assessing Atopic Dermatitis: Tools, Scoring Systems, and Patient-Centered Goal Setting

ByAngela J. Lamb, MD

June 29th 2026

FDA approval | Image Credit: Tada Images - stock.adobe.com

FDA Expands Risankizumab Approval to Pediatric Plaque Psoriasis, Active PsA

ByBrooke McCormick

June 29th 2026

Trending on AJMC

COVID-19 May Follow A Different Seasonal Pattern Than Influenza, RSV

What Comes Next: Taking on Unanswered Questions in Multiple Myeloma

New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000

FDA Expands Risankizumab Approval to Pediatric Plaque Psoriasis, Active PsA

Treatment for Thyroid Eye Disease Approved by FDA